Combination therapy for the treatment of benign prostatic hyperplasia
US6410554B1 · kind B1 · utility
Assignee
Inventors
Key dates
| Filing date | Mar 23, 1999 |
| Grant date | Jun 25, 2002 |
| Priority date | — |
| Expiry date | Mar 23, 2019 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K31/505
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
This invention relates to combination therapy for the treatment of benign prostatic hyperplasia comprising an alpha-1a antagonist and an endothelin antagonist. More specifically, the use of a selective alpha-1a adrenergic receptor antagonist in combination with a subtype non-selective endothelin antagonist provides relief of lower urinary tract symptoms in patients with symptomatic prostatism or benign prostatic hyperplasia. This combination therapy improves lower urinary tract symptoms including increasing urine flow rate, decreasing residual urine volume and improving overall obstructive and irritative symptoms in patients with benign prostatic hyperplasia or symptomatic prostatism.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.